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Abstract
The tumor suppressor p16Ink4a, encoded by the INK4a gene, is an inhibitor of cyclin D-
dependent kinases 4 and 6, CDK4 and CDK6. This inhibition prevents the phosphorylation
of the retinoblastoma protein (pRb), resulting in cellular senescence through inhibition of
E2F-mediated transcription of S phase genes required for cell proliferation. The p16Ink4a
plays an important role in tumor suppression, whereby its deletion, mutation, or epigenetic
silencing is a frequently observed genetic alteration in prostate cancer. To assess its roles
and related molecular mechanisms in prostate cancer initiation and progression, we gener-
ated a mouse model with conditional deletion of p16Ink4a in prostatic luminal epithelium. The
mice underwent oncogenic transformation and developed prostatic intraepithelial neoplasia
(PIN) from eight months of age, but failed to develop prostatic tumors. Given the prevalence
of aberrant androgen signaling pathways in prostate cancer initiation and progression, we
then generated R26hARL/wt:p16L/L: PB-Cre4 compound mice, in which conditional expres-
sion of the human AR transgene and deletion of p16Ink4a co-occur in prostatic luminal epithe-
lial cells. While R26hARL/wt:PB-Cre4 mice showed no visible pathological changes,
R26hARL/wt:p16L/L: PB-Cre4 compound mice displayed an early onset of high-grade PIN
(HGPIN), prostatic carcinoma, and metastatic lesions. Strikingly, we observed tumors
resembling human sarcomatoid carcinoma with intermixed focal regions of signet ring cell
carcinoma (SRCC) in the prostates of the compound mice. Further characterization of these
tumors showed they were of luminal epithelial cell origin, and featured characteristics of epi-
thelial to mesenchymal transition (EMT) with enhanced proliferative and invasive capabili-
ties. Our results not only implicate a biological role for AR expression and p16Ink4a deletion
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Introduction
Mounting evidence has shown aging to be one of the most important risk factors for human
prostate cancer (reviewed in [1]). Aging leads to decreased regenerative capability and an
increased risk of malignant transformation (reviewed in [2]). The tumor suppressor p16INK4a
has been shown to play a critical role in cellular aging and proliferation [3, 4]. An inhibitor of
cyclin D-dependent kinases, 4 and 6, p16INK4a prevents phosphorylation of the retinoblastoma
protein (pRb), which inhibits the transcription of E2F-regulated genes required for cell cycle
entry at the G1/S checkpoint [3, 5]. The suppressive role of p16Ink4a on cell cycle progression is
frequently disrupted in tumor cells, either by deletions or inactivating mutations of p16Ink4a
[6] or pRb [7]. The expression of p16Ink4a is generally low in normal tissue [8]. The tumor sup-
pressor role of p16Ink4a can be initiated by a number of distinct stimuli, including oncogenic
stress, DNA-damage, and aging [9]. It has been shown that deletion of p16Ink4a occurs in
human prostate cancer [10, 11]. Conversely, a suppressive growth effect of the induced expres-
sion of p16Ink4a has been observed in a prostate cancer xenograft model [12]. These lines of evi-
dence suggest a pivotal role of p16Ink4a in prostate tumorigenesis.
Androgen signaling, mediated through the AR and its ligands, testosterone and 5α-dihy-
drotestosterone (DHT), plays a critical role in prostate tumorigenesis [13–17]. The AR is a
member of the nuclear hormone receptor superfamily [18, 19]. The unbound AR forms a com-
plex with heat-shock proteins (HSPs) [20, 21]. Upon binding to a ligand, the AR dissociates
from the HSPs and translocates into the nucleus, where it binds to the androgen responsive
element (ARE), recruits cofactors [22], and activates its targeted gene expression, which in
turn controls prostate development and tumorigenesis. Aberrant activation of the AR directly
promotes prostate cancer cell growth and survival, and androgen deprivation therapy (ADT)
has been a standard treatment for prostate cancer for many decades [23]. However, many
patients eventually relapse after therapy and develop castration resistant prostate cancer
(CRPC) [13, 15, 24]. An important re-occurring element in prostate cancer is hormone refrac-
toriness, the reemergence of androgen signaling through a variety of molecular mechanisms
[13, 15]. Global gene expression profiling has shown the AR to be the only gene to be consis-
tently up-regulated in CRPC [24]. Alterations of AR activity through mutation [25], amplifica-
tion [26], overexpression [24], or cross-talk between AR and other growth factor pathways
[27] directly contribute to tumor progression and CRPC development [28].
While abnormal expression and deletion of p16Ink4a have been observed in human prostate
cancers [10, 11], its roles and related molecular mechanisms in prostate cancer initiation and
progression are poorly understood. In addition, there is no mouse model that can directly
assess the role of p16Ink4a and the collaborative effect of p16Ink4a suppression and AR activation
in prostate tumorigenesis. In this study, we first developed a conditional p16Ink4a deletion
mouse strain, in which the mouse p16Ink4a gene was selectively deleted in prostatic luminal epi-
thelium. Intriguingly, deletion of p16Ink4a alone was sufficient to induce oncogenic transforma-
tion and mouse prostatic intraepithelial neoplasia (PIN) from eight months of age. However,
the PIN lesions failed to progress to prostatic tumors in the mice, suggesting that additional
hits are required for tumor formation. Given the prevalent role of androgen signaling in
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prostate cancer initiation and progression, we generated R26hARL/wt:p16L/L: PB-Cre4 com-
pound mice, where conditional expression of the human AR transgene and deletion of
p16Ink4a co-occur in prostatic luminal epithelial cells. The R26hARL/wt:p16L/L: PB-Cre4 com-
pound mice revealed an earlier onset of PIN as well as prostatic carcinomas. Moreover, we
identified a rare form of highly malignant tumor, sarcomatoid carcinoma with signet ring cell
carcinoma (SRCC) in R26hARL/wt:p16L/L: PB-Cre4 compound mice [29–31]. These results not
only implicate a biological role for transgenic AR expression and p16Ink4a deletion in the path-
ogenesis of prostatic SRCC but also provide a new and unique GEM model for investigating
the molecular mechanisms for SRCC development.
Results
Conditional deletion of p16Ink4a in mouse prostate epithelium induces
oncogenic transformation and prostatic intraepithelial neoplasia
formation
Aberrant expression of p16Ink4a has been detected in human prostate cancer samples [10, 11,
32]. To directly investigate the biological role of p16Ink4a in prostate tumorigenesis, we gener-
ated a mouse line, p16L/L:PB-Cre4, in which p16Ink4a was conditionally deleted in prostatic
luminal epithelium using a modified probasin promoter, ARR2PB, (Fig 1A) [33]. Using geno-
mic PCR approaches, we confirmed the Cre/LoxP-mediated recombination of p16Ink4a in the
mouse prostate (Fig 1B). The p16L/L:PB-Cre4 offspring were born at the expected Mendelian
ratios and appeared normal with no obvious differences from their wild-type littermates at
birth. Per the recommendations of the Mouse Models of Human Cancers Consortium Prostate
Pathology Committee [34], we assessed p16L/L:PB-Cre4 mice from birth and identified patho-
logical lesions resembling low-grade prostatic intraepithelial neoplasia (LGPIN) in eight
month old p16L/L:PB-Cre4 mice (Fig 1C). These lesions originated predominantly in the dor-
sal/lateral prostate (D/LP) and ventral prostate (VP) lobes (Fig 1C1 and Fig 1C2, respectively),
consisting of atypical proliferative patterns with occasional stratification of cells and papillary
structures. These atypical lesions contained epithelial cells that appeared larger than adjacent
normal cells and lacked normal polarity (Fig 1C1’-2’). Development of these lesions in p16L/L:
PB-Cre4 mice suggests a tumor suppressive role of p16Ink4a in prostatic epithelium. However,
the animals with these lesions failed to develop prostate tumors after twenty-four months of
age (Fig 2E). This implies that other genetic and/or epigenetic alterations are required in com-
bination with p16Ink4a deletion for the formation of a prostate cancer.
Simultaneous expression of AR and deletion of p16Ink4a in the prostate
accelerates oncogenic transformation in the mouse prostate
Genetic alterations of AR frequently occur during the course of prostate cancer initiation and
progression in the presence of other genetic and epigenetic changes [24, 35, 36]. Given the
prevalence of alterations in androgen signaling in human prostate cancers, we generated
R26hARL/wt:p16L/L:PB-Cre4 compound mice, in which conditional AR expression and p16Ink4a
deletion co-occur in prostate epithelium (Fig 1D). While the AR transgene and/or p16Ink4a
target alleles were detected in various tissues isolated from R26hARL/wt:PB-Cre4 and R26hARL/wt:
p16L/L:PB-Cre4 mice (black or blue solid arrows, Fig 1E), the activated AR transgene or p16Ink4a
deleted alleles were detected exclusively in prostate tissues.(Black or blue empty arrows, Fig 1E).
Using co-immunofluorescence (co-IF), we assessed the expression of the AR transgene and
p16Ink4a deletion in the prostate tissues isolated from mice of each genotype. The expression of
transgenic human AR protein was only detected in prostatic epithelial cells of R26hARL/wt:
Collaborative roles of p16 and androgen signaling in prostate tumorigenesis
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PB-Cre4 and R26hARL/wt:p16L/L:PB-Cre4 mice (Fig 1F1 and Fig 1H1). Similarly, p16Ink4a expres-
sion presented in prostatic luminal epithelium of R26hARL/wt:PB-Cre4 mice (Fig 1F2) but was
Fig 1. Generation of p16Ink4a conditional deletion and AR conditional transgenic mice. (A) A scheme was shown of the
conditional p16Ink4a deletion target construct. (B) Genomic PCR was used to confirm the p16Ink4a targeting allele (blue
solid arrow) and deleted allele (blue empty arrow) of different mouse tissues. (C) Representative H&E of the prostate tissue
was shown for dorsal/lateral prostate (DLP), C1, and ventral prostate (VP), C2, for p16L/L:PB-Cre4 mice. (D) A scheme was
shown of the conditional AR transgene target construct and the p16Ink4a deletion target construct. For the AR transgene
construct, a PGK-neomycin cassette was flanked with loxP sites (LSL), red triangles, inserted between the CAG promoter
and a FLAG-tagged AR coding sequence. For the p16nkK4a deletion, two LoxP sites, red triangles, were inserted to flank
exon 1 alpha. Targeting constructs were shown, upper and Cre-driven recombined alleles for both constructs are shown
below. (E) Genomic PCR was used to confirm the AR (black solid arrow) or p16Ink4a (blue solid arrow) targeting allele and
AR recombined (black empty arrow) or p16Ink4a deleted (blue empty arrow) allele from different tissues of R26hARL/wt:
PB-Cre4 and R26hARL/wt:p16L/L:PB-Cre4 mice. (F-H) Immunofluorescence (IF) assays. Prostate tissues of R26hARL/wt:
PB-Cre4, p16L/L:PB-Cre4, and R26hARL/wt:p16L/L:PB-Cre4 mice were used for IF analyses and tissues sections were probed
for AR (red, F1, G1, H1) or p16INK4a (green, F2, G2, H2) and DAPI (blue, F3, G3, H3), respectively.
https://doi.org/10.1371/journal.pone.0211153.g001
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Fig 2. Histological and immunohistochemistry analyses of the prostate from R26hARL/wt:PB-Cre4, p16L/L:PB-Cre4 and R26hARL/wt:p16L/L:PB-Cre4.
(A-B) Representative H&E images of the prostate tissue was shown for AP, DLP, and VP for R26hARL/wt:PB-Cre4 (A1-A3, magnification A1’-A3’) and
R26hARL/wt:p16L/L:PB-Cre4 mice (B1-B3, magnification B1’-B3’). Scale bar used was 100 μm or 25 μm. (C). Representative H&E and IHC images of adjacent
prostate tissue sections of AP from the p16L/L:PB-Cre4 mice were shown for staining with different antibodies as labeled in right bottom corner. (D).
Representative H&E and IHC images of adjacent prostate tissue sections from the p16L/L: R26hARL/wt:PB-Cre4 mice were shown for staining with different
antibodies (please see S1B and S1B’ Fig for positive staining of synaptophysin). Scale bar used was at 25 μm for all panels (C1-D9). (E) Pathological
abnormalities of R26hARL/wt:PB-Cre4, p16L/L:PB-Cre4, and R26hARL/wt:p16L/L: PB-Cre4 mice reported for different time points.
https://doi.org/10.1371/journal.pone.0211153.g002
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absent in the samples of p16L/L:PB-Cre4 and R26hARL/wt:p16L/L:PB-Cre4 mice (Fig 1G2 and Fig
1H2). These data confirmed conditional expression of the AR transgene and deletion of p16Ink4a
co-occur in the prostate of the R26hARL/wt:p16L/L:PB-Cre4 compound mice.
The R26hARL/wt:p16L/L: PB-Cre4 mice and their littermates, R26hARL/wt:PB-Cre4, were
born at the expected Mendelian ratios. They appeared normal with no obvious physical differ-
ences from their wild-type littermates at birth. Gross and pathological analyses showed no
obvious abnormalities in the prostate of R26hARL/+:PB-Cre4 mice (Fig 2E), which is consistent
with previous reports [37, 38]. All prostatic lobes displayed normal prostatic epithelium con-
sisting of a single uniform layer of both luminal and basal cells (Fig 2A1-3’). Intriguingly, we
observed that R26hARL/wt:p16L/L:PB-Cre4 compound mice developed PIN in all prostatic lobes
(Fig 2B1-3 versus Fig 1C1-2), suggesting that the atypical lesions observed in the p16 knock-
outs were indeed precursor lesions. Specifically, pathological changes resembling high grade
PIN (HGPIN) occurred within the anterior prostate (AP), containing atypical cells filling the
lumen of the ducts, large pleomorphic nuclei with prominent nucleoli, and nuclear hyperchro-
masia (Fig 2B1-3’). Using immunohistochemical (IHC) approaches, the cellular properties of
atypical cells within PIN lesions of p16L/L:PB-Cre4 mice and R26hARL/wt:p16L/L: PB-Cre4 com-
pound mice were assessed. Positive nuclear staining of human AR protein only appeared in
atypical cells of the prostate tissues of R26hARL/wt:p16L/L: PB-Cre4 compound mice (Fig 2C2
and Fig 2D2). However, positive staining of mouse AR revealed in the nucleus of luminal cells
of both p16L/L:PB-Cre4 (Fig 2C3) and R26hARL/wt:p16L/L: PB-Cre4 compound mice (Fig 2D3).
Loss of p16Ink4a staining was observed in prostate tissues of both p16L/L:PB-Cre4 (Fig 2C4) and
R26hARL/wt:p16L/L:PB-Cre4 compound mice (Fig 2D4), whereas the p16Ink4a expression was
detected in R26hARL/wt:PB-Cre4 mice (S1A and S1A’ Fig). Most of the atypical cells within
PIN lesions from both p16L/L:PB-Cre4 and R26hARL/wt:p16L/L: PB-Cre4 mice showed positive
staining for E-cadherin (Fig 2C5 and Fig 2D5) and cytokeratin-8, CK8, (Fig 2C6 and Fig 2D6),
which was consistent with their luminal epithelial origin. A scattered subset of cells were
immunoreactive to the basal cell markers cytokeratin-5, CK5, (Fig 2C7 and Fig 2D7) and p63
(Fig 2C8 and Fig 2D8), but no staining for the neuroendocrine cell marker synaptophysin (Fig
2C9 and Fig 2D9) was seen in the prostate tissues from mice of either genotype. Taken
together, the above results demonstrate that simultaneous expression of AR and deletion of
p16Ink4a accelerates, and is necessary for oncogenic transformation in the mouse prostate, and
that the atypical cells within the PIN lesions of the both p16L/L:PB-Cre4 and R26hARL/wt:p16L/L:
PB-Cre4 mice are prostatic luminal cell in origin.
Development of prostate tumors possessing simultaneous expression of AR
transgene and loss of p16Ink4a expression in prostate epithelium
Based on the reported observations that HGPIN lesions can develop into prostate adenocarci-
noma [39, 40], we continued examining p16L/L:PB-Cre4 and R26hARL/wt:p16L/L:PB-Cre4 mice
at advanced age. There was no observable progression of the focal atypical lesions in p16L/L:
PB-Cre4 mice after twenty four months (Fig 2E and Fig 3A), suggesting the deletion of p16Ink4a
alone in the prostate is not sufficient for formation of malignancy in mice. In contrast, prostate
carcinoma developed in R26hARL/wt:p16L/L:PB-Cre4 compound mice (Fig 3A). The invasive
prostatic carcinomas were observed at eight months of age and increased incidence was
observed in R26hARL/wt:p16L/L:PB-Cre4 mice over twelve months of age (Fig 2E).
Intriguingly, intracystic adenocarcinomas, invasive adenocarcinomas, and sarcomatoid
carcinomas were observed (Fig 3B and Fig 3C). The co-existence of these tumor types in the
R26hARL/wt:p16L/L:PB-Cre4 mice could be evidence of disease progression. These neoplastic
lesions included characteristic regions of HGPIN (Fig 3B1 and Fig 3C1), multi-focal, poorly
Collaborative roles of p16 and androgen signaling in prostate tumorigenesis
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differentiated adenocarcinomas (Fig 3B2 and Fig 3C2), areas of increased proliferative activity
and necrosis (Fig 3B3), as well as moderately differentiated adenocarcinoma (Fig 3C3). Adja-
cent to lesions of intracystic adenocarcinomas were regions classified as invasive sarcomatoid
carcinoma, which was the dominant pathologic feature in all cases (Fig 3B4 and Fig 3C4).
The cellular properties of prostatic adenocarcinoma were assessed using IHC in tumor tis-
sues of R26hARL/wt:p16L/L:PB-Cre4 mice. A typical nuclear staining for the transgenic AR was
observed in most tumor cells, providing a direct link between the expression of the human AR
transgene and tumor development (Fig 3D2). The tumor cells also showed positive staining
for endogenous mouse AR, E-cadherin, and CK8 (Fig 3D3-5), the hallmarks of prostatic lumi-
nal epithelium. These tumor cells were negative for the basal epithelial cell markers p63 and
CK5 (Fig 3D6-7), as well as for the neuroendocrine cell marker synaptophysin (Fig 3D8).
These results demonstrate that the prostatic adenocarcinomas possess the same luminal
Fig 3. Synergistic effect of conditional AR expression and p16Ink4a deletion accelerates formation of adenocarcinoma. (A) Pathological abnormalities of
the prostate were listed for both p16L/L:PB-Cre4 and R26hARL/wt:p16L/L:PB-Cre4 mice. (B-C) Representative image of prostatic tumors from R26hARL/wt:p16L/L:
PB-Cre4 mice. Scale bar used was at 200 μm. B1-C4. Pathological dissemination of typical morphological characteristics of HGPIN (B1, C1) adenocarcinoma
(B2, C2 and C3) and regions of necrosis (B3) and sarcomatoid carcinoma (B4, C4). D1-D8. Representative H&E and IHC images of adjacent prostate tissue
sections of adenocarcinoma lesions from the R26hARL/wt:p16L/L:PB-Cre4 mice were shown for staining with different antibodies (right bottom corner). Scale
bar used was at 25 μm for all panels (B1-D8).
https://doi.org/10.1371/journal.pone.0211153.g003
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prostatic cell properties as observed in PIN lesions of R26hARL/wt:p16L/L:PB-Cre4 mice, indi-
cating a luminal epithelial origin.
In this study, diffuse, poorly differentiated lesions with biphasic epithelial and mesenchymal
properties were observed in the prostatic stroma of R26hARL/wt:p16L/L:PB-Cre4 mice over
twelve months of age (Fig 2E). These are classified as sarcomatoid carcinomas and are biphasic
malignant neoplasms with features of epithelial-mesenchymal transition (EMT) (reviewed in
[34] [41]). As shown in Fig 4A and Fig 4B, these lesions have tumor cells with a spindle-cell
morphology (Fig 4A1 and Fig 4B1), focal regions of necrosis (Fig 4A2), and increased mitotic
figures (Fig 4A3-3’ and 4B3-3’), indicative of a highly proliferative cell population in these sar-
comatoid carcinomas. Invasion of the spindle-like tumor cells into surrounding muscle layers
also appeared within the tumor samples (Fig 4B2). Development of this type of invasive pros-
tatic carcinoma in this model suggests a collaborative role of AR activation and p16Ink4a dele-
tion in prostate cancer initiation and progression.
Our observation of sarcomatoid carcinomas adjacent to areas of PIN and invasive adeno-
carcinoma in the prostate tissues of R26hARL/wt:p16L/L:PB-Cre4 mice suggests that the sarco-
matoid carcinomas may have developed from PIN and prostatic adenocarcinomas. To test this
hypothesis, we assessed the properties of sarcomatoid carcinoma (Fig 4C1). IHC revealed posi-
tive nuclear staining for mouse AR in spindle-like tumor cells, suggesting an origin of the AR-
positive luminal epithelial cells (Fig 4C2). The tumor cells also showed positive staining for
CK8 (Fig 4C3) but not E-cadherin, CK5, p63, or synaptophysin (Fig 4C5-8). Using co-IF, co-
expression of CK8 and the mesenchymal cell marker vimentin in tumor cells was observed
(Fig 4D1-4). Loss of E-cadherin, an epithelial marker, expression was confirmed in these CK8-
and vimentin-positive cells (Fig 4E1-4). The expression of AR and CK8 but loss of E-cadherin
suggests that the sarcomatoid carcinomas retain luminal epithelial cell properties and undergo
EMT, providing a clear evidence of disease progression.
We examined the proliferative activity of the cells in tumor lesions from R26hARL/wt:p16L/L:
PB-Cre4 mouse prostates. Using IHC, we measured the expression of the proliferation marker
Ki67 in normal and aberrant pathological lesions in each sample. An increase in Ki67 staining
in areas of PIN, prostatic adenocarcinoma, and sarcomatoid carcinoma was observed when
compared to normal prostatic tissues (Fig 4F). Notably, there were approximately 200 Ki67-
positive cells per 1000 cells within the sarcomatoid carcinoma lesions (Fig 4F), which was sig-
nificantly higher than those in PIN or prostatic adenocarcinoma lesions. These observations
are consistent with the frequent appearance of mitotic figures presented in Fig 4A3’ and Fig
4B3’, and demonstrate the highly proliferative nature of the sarcomatoid carcinoma cells.
Development of signet ring cell carcinoma in the prostate and metastatic
sites of R26hARL/wt:p16L/L:PB-Cre4 mice
Intermixed with regions of both the prostate adenocarcinoma and sarcomatoid carcinoma
lesions of R26hARL/wt:p16L/L:PB-Cre4 compound mice was a tumor subtype with a particularly
unique phenotype. Upon pathological examination of the tumor samples a distinct population
of cells resembling signet ring cells (SRC) was observed, featuring large eosinophilic vacuoles
displacing the nucleus to the cell periphery [42]. These prostatic SRCs appeared in various pro-
portions in sarcomatoid carcinoma including up to 100% of some regions (Fig 5A1-2 and Fig
5B1-2). High magnification visualization of these tumor lesions showed typical SRC morphol-
ogy (Arrows, Fig 5A1’-2’ and Fig 5B1’-2’). It has been shown that intracytoplasmic mucins
within the large eosinophilic vacuoles were frequently detected in SRCs [43]. To evaluate the
status of neutral mucinous components within the SRCs in the R26hARL/wt: p16L/L:PB-Cre4
mouse tumors, we performed Periodic Acid Schiff (PAS) and PAS-Diastase (PAS-D) staining.
Collaborative roles of p16 and androgen signaling in prostate tumorigenesis
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Fig 4. Simultaneous conditional expression of AR transgene and loss of p16Ink4a expression induce sarcomatoid
carcinoma development. (A-B) Representative images of two tumor samples display the region of sarcomatoid
carcinoma. Scale bar = 200 μm. Representative images of different lesions are shown, including sarcomatoid
carcinoma (A1, B1), area of necrosis (A2), invasion into muscle (B2), and images of mitotic figures (A3, B3, see the
arrows). (C) Representative H&E and IHC images from the R26hARL/wt:p16L/L:PB-Cre4 mice were shown for staining
with different antibodies as labeled in the right bottom corner. (D-E) Co-IF from the R26hARL/wt:p16L/L:PB-Cre4 mice
of secretory epithelial cell marker CK8 (green), mesenchymal cell marker vimentin (red), and DAPI (blue), upper
panels; Co-IF of secretory epithelial cell marker E-cadherin (green) and mesenchymal cell marker vimentin (red) and
DAPI (blue), lower panels. F. R26hARL/wt:p16L/L: PB-Cre4 mouse tissues were stained and quantified for Ki67 for the
above tissues were measured in total 1,000 epithelial cells. Representative data shows mean and standard deviation. ��
p< 0.005 Scale bar = 25 μm and magnifications were at 12.5 μm (A1-E4).
https://doi.org/10.1371/journal.pone.0211153.g004
Collaborative roles of p16 and androgen signaling in prostate tumorigenesis
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Fig 5. Histological and Immunochemical identification of signet ring cell carcinoma. (A-B) Representative image of the prostate signet ring cell
carcinomas, SRCCs, in R26hARL/wt:p16L/L:PB-Cre4 mice. Scale bar = 200 μm. A1-B2. Pathological characterization of typical morphological
characteristics of SRCC was highlighted in two different tumor samples with magnified views (A1’- B2’). (C-F) Representative view is shown for
PAS/PAS (C-D, magnified view C’-D’) staining, Alcian Blue staining (E, magnified view E’), and vimentin immunoreactivity (F, magnified view F’).
Scale bar used was at 50 μm and magnified views scale bar used was at 12.5 μm. (G). Representative view of IHC images of adjacent prostate tissue
sections of signet ring cell carcinoma lesion from the R26hARL/wt:p16L/L:PB-Cre4 mice are shown for staining with different antibodies (right
bottom corner). Scale bar used was at 12.5 μm. (H-J) Representative images of H&E of metastatic lesions in the lung (H), liver (I), and Lymph node
(J) with magnified views (H’-J’). (K) Pathological abnormalities of the different aged mice were listed for R26hARL/wt:p16L/L: PB-Cre4 mice.
Scale = 50 μm, or 12.5 μm (C-F, H-J).
https://doi.org/10.1371/journal.pone.0211153.g005
Collaborative roles of p16 and androgen signaling in prostate tumorigenesis
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As shown in S1C to S1D’ Fig, positive staining of both PAS and PAS-Diastase were revealed in
liver tissues of wild type mice. However, there was no positive staining with PAS and PAS-D
in prostate tissues with SRC lesions (Fig 5C’ and Fig 5D’). Staining with Alcian Blue was also
negative in the above prostate tissues containing SRCC (Fig 5E and Fig 5E’), in the contrast to
the positive control samples (S1E and S1E’ Fig). These results suggest the absence of mucinous
components and proteoglycans in SRCs of R26hARL/wt:p16L/L: PB-Cre4 mice. Identification of
prostatic SRCC in the R26hARL/wt:p16L/L:PB-Cre4 mouse model is novel and provides a useful
tool for investigating signet ring cell carcinomas in the future. Using IHC approaches, we fur-
ther assessed the cellular properties of the prostatic SRCs. Notably, the SRCs were immunore-
active with antibodies against vimentin (Fig 5F and Fig 5F’), AR (Fig 5G1), and CK8 (Fig
5G2), but not for E-cadherin (Fig 5G3), CK5 (Fig 5G4), p63 (Fig 5G5), or synapotphysin (Fig
5G6) respectively. These results demonstrate a prostatic SRC expression pattern similar to the
spindle-like sarcomatoid carcinoma cells, suggesting that these tumor lesions may be derived
from the same cell origin.
During the course of our investigation, we closely monitored the mice for metastases in dis-
tant organs. Interestingly, we identified metastatic lesions in three R26hARL/wt:p16L/L:PB-Cre4
mice over twelve months of age (Fig 5K). Histological analyses showed metastatic tumor
lesions, in the lung (Fig 5H and Fig 5H’), liver (Fig 5I and Fig 5I’), and lymph nodes (Fig 5J
and Fig 5J’). Each of these metastatic lesions was composed primarily of spindle-like cells with
focal regions of SRCs. IHC analyses of the SRCs in metastatic lesions revealed similar cellular
properties to those in the primary tumors of R26hARL/wt:p16L/L:PB-Cre4 mice. SRCs in meta-
static tissues from the lung were positive for AR and CK8, but negative for E-cadherin and
CK5 (S2 Fig). These data confirm the prostatic cell origin of the metastatic disease and provide
an additional line of evidence demonstrating the highly aggressive features of prostatic SRCC
in R26hARL/wt:p16L/L: PB-Cre4 compound mice.
Identification of downstream targets that promote prostate tumor
initiation and progression
In search for the molecular basis by which transgenic AR expression and p16INK4a deletion reg-
ulate prostate tumorigenesis, we performed RNA-sequencing analysis to examine the global
transcriptome profiles in the mouse prostate tumor samples. Given that HGPIN and prostate
tumor development respectively occurred in p16L/L:PB-Cre4 and R26hARL/wt:p16L/L:PB-Cre4
mice, we focused specifically on those mice. RNA transcriptome profiling yielded differentially
expressed genes (DEGs) of 960 genes that were upregulated with a fold change� 5 and 537
genes that were downregulated at a fold change� 5 from samples of the p16L/L:PB-Cre4 and
R26hARL/wt:p16L/L: PB-Cre4 mice in comparison to those from age and sex-matched wild type
littermates (S1 Table). The change in expression of these genes reflects the activity of either
p16Ink4a deletion alone or in combination with transgenic AR expression in the mouse pros-
tate. According to gene set enrichment analysis (GSEA), the hallmark EMT signature was the
most significantly enriched in the R26hARL/wt:p16L/L:PB-Cre4 compound mice (S3B Fig) [44].
Forty-nine DEGs within our data set overlapped with the hallmark EMT signature gene set
(200 genes) (S3A Fig). Using real-time quantitative RT-PCR, qRT-PCR, alteration of a subset
of these genes was validated (Fig 6A). We confirmed the statically significant upregulation of
Spp1, Timp1, Twist, Sfrp4, Foxg1, Adam12, Cd44, and Itgb1 in the R26hARL/wt:p16L/L:PB-Cre4
mice in comparison to p16L/L: PB-Cre4 and wild type mice (Fig 6B). IHC analyses showed
increased expression of Spp1 and CD44 in the prostates of the R26hARL/wt:p16L/L:PB-Cre4
mice relative to the p16L/L: PB-Cre4 mice (Fig 6C1-2’ versus Fig 6D1-2’). The above data
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provide a molecular basis for the effect of transgenic AR expression and p16Ink4a deletion in
prostate cancer progression.
Fig 6. Co-expression of AR transgene and loss of p16Ink4a expression induces an EMT signature. (A) Heatmap showing a
subset of differentially expressed genes (DEGs) that corresponded to an overlap of hallmark EMT genes comparing p16L/L:
PB-Cre4 and R26hARL/wt:p16L/L: PB-Cre4 mice. (B) qRT-PCR confirmation of the gene alterations in prostate tissues of
p16L/L: PB-Cre4 and R26hARL/wt:p16L/L: PB-Cre4. The data is presented as the mean ± (SD) (n = 3) �� p< 0.005 and �
p< 0.01 by student’s T test. (C-D) Representative view of IHC images of adjacent prostate tissue sections of sarcomatoid
carcinoma lesion from the R26hARL/wt:p16L/L: PB-Cre4 mice (C1-C2) and p16L/L: PB-Cre4 mice (D1-D2) and their
magnified views (C1’-D2’). Scale bar = 50 μm or 12.5 μm.
https://doi.org/10.1371/journal.pone.0211153.g006
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Discussion
Loss of the CDK4/6 inhibitor, p16INK4a, due to its deletion or reduced expression through pro-
moter hyper-methylation, has been observed in human prostate cancer samples [32, 45, 46].
Although the oncogenic role of p16Ink4a loss has been investigated in several tumor types [47–
49], the loss of the tumor suppressor in prostate tumorigenesis has not been evaluated in a rele-
vant mouse model. In this study, we developed a novel mouse model, p16L/L:PB-Cre4 mice,
where the p16Ink4a gene was selectively deleted in prostatic luminal epithelial cells through Cre-
LoxP-mediated recombination. We observed the development of mouse prostatic intraepithe-
lial neoplasia in p16L/L:PB-Cre4 mice at eight months of age, providing the first line of evidence
demonstrating that p16Ink4a deletion can initiate oncogenic transformation and PIN formation
in the mouse prostate. In this study, we did not observe further severe pathologic changes in
p16L/L:PB-Cre4 mice, suggesting that deletion of p16Ink4a alone is not sufficient to induce pro-
gression to prostate cancer. The precise mechanisms for this observation are currently unclear,
potentially requiring additional genetic alterations for p16Ink4a-mediated tumor development
in the prostate. The current mouse model, p16L/L:PB-Cre4 mice, is a biologically relevant
experimental tool for identification of such alterations in the initiation of malignant
transformation.
Aberrations of androgen signaling have been frequently identified in prostate cancer. Spe-
cifically, AR gene amplification or upregulation of the AR gene expression appears along with
other genetic and epigenetic alterations in human prostate tumor tissues [35, 36]. Given the
significance of both AR and p16Ink4a alterations in human prostate cancers, we developed
R26hARL/wt:p16L/L:PB-Cre4 compound mice in which the deletion of the p16Ink4a gene and
conditional expression of the human AR transgene co-occur in the prostatic luminal epithe-
lium. We observed accelerated PIN development in R26hARL/wt:p16L/L:PB-Cre4 compound
mice. We did not find any significant abnormality in the R26hARL/wt:PB-Cre4 mice. In con-
trast to 20% of the p16L/L:PB-Cre4 mice developing PIN lesions, the R26hARL/wt:p16L/L:
PB-Cre4 compound mice showed PIN penetrance of 70%. This evidence demonstrates that the
combined upregulation of AR and deletion of p16INK4a enhances oncogenic transformation in
mouse prostate epithelium. Intriguingly, about 20% of the compound mice developed prostatic
invasive carcinomas, sarcomatoid carcinomas, SRCCs, and metastatic tumors. Despite the
aggressiveness of the above tumor phenotypes, the level of penetrance suggests that other
genetic and epigenetic factors are required for tumor formation, progression, and metastasis.
In this study, we also observed aged mice showing increased tumor incidence and more
aggressive tumor phenotypes, indicating a clear inverse correlation between aging and progno-
sis in the compound mice. All mice over 12 months of age bearing adenocarcinomas also
developed invasive sarcomatoid carcinoma with SRCC, and metastatic disease. Not only do
these data demonstrate a collaborative effect of AR expression and deletion of p16INK4a in pro-
moting prostate cancer initiation and progression, but also provide a new and biological rele-
vant mouse model that mimics the age-dependent human prostate cancer phenotypes.
As described in this study, we observed a variety of pathologic changes in the prostate of
R26hARL/wt:p16L/L:PB-Cre4 compound mice. In addition to HGPIN and prostatic adenocarci-
nomas, we also identified sarcomatoid carcinoma that was the dominant pathologic feature
and signet ring cell carcinoma lesions in the compound mice. Prostatic sarcomatoid carcino-
mas included spindle-like cells with highly proliferative and aggressive growth features, and
invasion into the neighboring stroma. IHC analyses showed positive staining for AR in tumor
cells within sarcomatoid carcinoma lesions, indicating that they originated from prostatic epi-
thelium and, perhaps, PIN and/or prostatic adenocarcinomas. In agreement with these obser-
vations, earlier clinical studies have shown that prostate cancer patients with sarcomatoid
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carcinomas also had prior history and diagnosis of prostatic adenocarcinoma [50, 51]. A study
of 42 patients showed approximately 66% of prostatic sarcomatoid cancer patients had prior
pathologic diagnoses of prostate adenocarcinomas [52]. Deletion of prostate-specific erythro-
blast transformation-specific-related gene (ERG) has been detected in both the sarcomatoid
and adjacent prostate adenocarcinoma, indicating that these two tumor types may be derived
from the same cell origin [53]. We also detected positive staining for vimentin, a mesenchymal
marker, in prostatic sarcomatoid tumor cells in the compound mice, suggesting the that these
sarcomatoid carcinomas are undergoing the EMT process.
Most notably from this study, we identified an tumor type pathologically resembling signet
ring cell carcinoma (SRCC), found as a part of the sarcomatoid carcinoma lesions in the
R26hARL/wt:p16L/L:PB-Cre4 compound mice. SRCC is a rare type of highly malignant adeno-
carcinoma in humans but has not been described in mice. It is of epithelial origin and is char-
acterized by cells featuring a crescent-shaped nucleus compressed against the cell membrane
due to a large cytoplasmic vacuole [54]. Primary SRCC tumors are most often observed in the
glandular cells of the stomach but also can be found in other tumor types, including prostate
cancer [43, 55]. SRCC possesses invasive characteristics and is capable of colonizing at distant
sites [29, 31, 56]. Previous studies have shown prostatic SRCCs to be highly aggressive with
poor survival rates [29–31, 55].
As shown in this study, we observed tumor lesions containing the morphology of SRC in
the prostate of R26hARL/wt:p16L/L:PB-Cre4 compound mice. IHC analyses further showed the
prostatic SRCs to be AR and CK8-positive, suggesting they are derived from prostatic luminal
cells. The positive staining with vimentin in the SRCs further indicates the EMT features of
SRCs. We also identified SRCs in metastatic tumor sites, including the lung, liver, and lymph
nodes. These multiple lines of experimental evidence indicate that prostatic SRCC in
R26hARL/wt:p16L/L:PB-Cre4 compound mice share many pathological and biological features
with human SRCCs. In this study, we also assessed the alterations of AR and p16Ink4a in
human prostatic SRCC samples. Interestingly, from a human tissue microarray, we found 7 of
7 samples displayed positive staining for AR, and 5 out of 7 showed absence or reduced stain-
ing for p16Ink4a (S2 Table). These data imply a possible role of AR and p16Ink4a in SRCC patho-
genesis, and warrant further investigation of patient samples.
Observation of sarcomatoid carcinoma and SRCC lesions with invasive and metastatic fea-
tures in R26hARL/wt:p16L/L:PB-Cre4 compound mice supports the pattern of tumor progres-
sion and EMT development. This suggests a collaborative role of transgenic AR and p16Ink4a in
enhancing tumor cell transdifferentiation and EMT promotion. We assessed this collaborative
program by RNA sequencing and quantified real-time PCR approaches to analyze the changes
of the transcriptional profiles from the prostate tumor samples isolated from p16L/L:PB-Cre4
and R26hARL/wt:p16L/L:PB-Cre4 mice. We observed an increase in the expression of a cluster of
genes related to EMT and tumor progression in tumor samples isolated from R26hARL/wt:
p16L/L:PB-Cre4 compound mice in comparison to those from p16L/L:PB-Cre4 mice. All
together these data provide the molecular basis for future investigations to identify the specific
regulators and signaling pathways that directly contribute to prostate cancer initiation and
progression in R26hARL/wt:p16L/L:PB-Cre4 compound mice.
Materials and methods
Ethics statement
All animal experiments performed in this study were approved by the ethics committee of the
Administrative Panel on Institutional Animal Care and Use Committee at Beckman Research
Institute/City of Hope.
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Mouse mating and genotyping
All mice that were used in this study were from a C57BL/6 background. Mice containing the
conditional p16Ink4a allele (p16LoxP/LoxP), also named p16L/L, were kindly provided by Dr. Sharp-
less at University of North Carolina [57]. The AR transgenic mouse strain, R26hARLoxP/wt
(R26hARL/wt) was generated previously [38]. Prostate specific conditional knockout mice were
generated using PB-Cre4 mouse strain [33]. We generated p16L/wt:R26hARL/wt mice by inter-
crossing p16L/L with R26hARL/wt mice. The experimental mice were produced from intercross-
ing of p16L/wt: R26hARL/wt and p16L/wt: PB-Cre4 mice to generate three goal mice with
genotypes: R26hARL/wt: PB-Cre4, p16L/L: PB-Cre4, and p16L/L:R26hARL/wt: PB-Cre4. Mice were
genotyped by PCR as described previously [38, 57]. Detection of the AR targeting allele used the
forward primer, 5’-TTCGGCTTCTGGCGTGTGAC-3’ with the reverse primer, 5’-CT
CTGGAACAGATTCTGGAAA-3’ and 5’-AGCGCATCGCCTTCTATCGCCTTC-3’. The
p16Ink4a conditional allele and deleted allele were detected with the forward, 5’-TACCACA
GTTTGAACAGCGTGA-3’ with the reverse primer, 5’-AACCAACTTCCTCCTTCCCC-3’,
and 5’-CCAAAACCACAACAGCTAGGA-3’. Genomic PCR conditions for AR recombined
allele were 95˚C for 3 min, then 95˚C for 30 sec, 64˚C for 30 sec, and 72˚C for 60 sec for 35
cycles, then 72˚C for 5 min. Genomic PCR conditions for p16Ink4a amplified at 95˚C for 3 min,
then 95˚C for 45 sec, 58˚C for 40 sec, and 72˚C for 60 sec for 35 cycles, then 72˚C for 5 min.
Histology and Immunohistochemistry, Immunofluorescence, PAS and
PAS/D, Alcian Blue staining and histological analysis
The new guidelines recommended by The Mouse Models of Human Cancers Consortium
Prostate Pathology Committee in 2013 were used for our pathological analyses [34]. Mouse tis-
sues were fixed in 10% neutral-buffered formalin and processed into paraffin as previously
described [38]. Mouse tissues were cut using 4 μm serial sections and rehydrated through a
decreasing ethanol gradient. Histology was visualized by hematoxylin-eosin (H&E) staining
performed as reported earlier [38]. Immunohistochemistry (IHC) included boiling the tissue
in 0.01 M citrate buffer (pH 6.0) for antigen retrieval, and then incubated in 0.3% H2O2 for 15
min. Samples were blocked in 5% normal goat serum for 30 min and then incubated with pri-
mary antibodies diluted in 1% normal goat serum at 4˚C overnight. Slides were incubated with
biotinylated secondary antibodies for 1 hour, and then incubated with streptavidin ligated to
horse radish peroxidase (HRP) (SA-5004, Vector Laboratories) for 30 min. Detection of HRP
was with the 3,3’-diaminobenzidine (DAB) kit (SK-4100, Vector Laboratories). Nuclei were
counterstained with 5% (w/v) Harris Hematoxylin and then mounted with Permount Medium
(SP15-500, Fisher Scientific). Immunofluorescence (IF) of tissue samples were processed the
same for IHC, except that the samples were incubated with fluorescent-conjugated secondary
antibodies for 1 hour, and then mounted with Vectashield Mounting Medium with DAPI (H-
1200, Vector Laboratories).
PAS staining was performed with the addition of 0.5% periodic acid (19840–0050, Acros)
for 5 min at room temperature and then washed with distilled water. The tissue glycogen was
digested with 0.5% Diastase (PAS/D) (AHDIA50, American MasterTech). Tissues were then
incubated in Schiff ‘s reagent (26312-1A, Electron Microscopy Sciences) for 15 min at room
temperature and then washed with tap water. Nuclei were counterstained with 5% (w/v) Harris
Hematoxylin and mounted with Permount Medium (SP15-500, Fisher Scientific). Tissue sam-
ples for Alcian Blue staining were incubated in 1% Alcian Blue and 3% Acetic Acid at pH 2.5
for 30 min and then washed in distilled water. Counterstaining with nuclear-fast red solution
was performed. After dehydration and clearing, the slides were mounted with Permount
Medium (SP15-500, Fisher Scientific).
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Antibodies
The primary antibodies used and their subsequent dilutions were: anti-P16 (rabbit, 1:1000,
SC-1207, Santa Cruz), anti-human AR (mouse, 1:250, sc-7305, Santa Cruz Biotechnology),
anti-CK5 (rabbit, 2400, PRB-160P, Covance), anti-CK8 (mouse, 1:2000, MMS-162P, Cov-
ance), anti-p63 (mouse, 1:2000, sc-8431, Santa Cruz), anti Ki67 (mouse, 1:1000, NCL-ki67,
Novacastra), anti-E-cadherin (mouse, 1:200, Cat. No. c20820, BD Transduction Laboratoriesc,
Sparks, MD, United States), anti-mouse/ human androgen receptor (rabbit, 1:250, sc-816,
Santa Cruz), anti-synaptophysin (rabbit, 1:100, Cat. No. 18–0130, Invitrogen), anti-SPP1 (rab-
bit, 1:200, Cat. No. 91655, Abcam, Cambridge, MA, USA), CD44 (Rat, 1:50, sc-18849, Santa
Cruz) and anti-Vimentin (Chicken, 1:2000, Cat. No. 919101, Biolegend). The biotinylated
anti-rabbit or anti-mouse secondary antibody (BA-1000 or BA-9200, Vector Laboratories), or
anti-rabbit or anti-mouse conjugated to AlexaFluor488 or to AlexaFluor594 (Molecular
Probes) secondary antibody that were used for IHC or IF staining, respectively.
Microscope image acquisition
Images of H&E and IHC were acquired on an Axio Lab. A1 microscope using 10x and 40x
Zeiss A-Plan objectives with a Canon EOS 1000D camera and using Axiovision software (Carl
Zeiss). Images of immunofluorescence staining were acquired on a Nikon ECLIPSE E800 epi-
fluorescence microscope using 20x and 40x Nikon Plan Fluor objectives with an QImaging
RETIGA EXi camera and using QCapture software (QImaging).
RNA isolation and qRT-PCR assay
Mouse prostate tissues were homogenized in RNA-Bee (TEL-TEST, Inc., Friendswood, TX,
USA), and total RNA was isolated as recommended by the manufacturer. Reverse transcrip-
tion was carried out following our previous report [58]. For quantitative PCR, cDNA samples
were mixed with SYBR greenER qPCR Super Mix Universal (11762, Invitrogen) and per-
formed quantitative RT PCR according to the manufacture’s protocol. Relative mRNA levels
were calculated by Delta Delta C(T) methods (KJ Livak, 2001, Method). Reactions were done
in triplicate, and the values were normalized by PPIA (peptidylprolyl isomerase A) expression
levels. Primers for SPP1 (5’- ATCTCACCATTCGGATGAGTCT- 3’; 5’- TGTAGGGACGA
TTGGAGTGAAA-3’), Timp1 (5’- TCTGGCATCCTCTTGTTGCT-3’; 5’- CATGAATTT
AGCCCTTATGACCAG-3’), Twist (5’- GCTACGCCTTCTCCGTCTG -3’; 5’- GAAACAA
TGACATCTAGGTCTCCG-3’), Sfrp4 (5’- GTCACTGACCTTCCAGAAGATGT-3’; 5’- CC
TTTTTGCACTTGCACCGA-3’), Adam12 (5’- TGGGGATGTGCCTCTTCAAC-3’; 5’- AT
TCGTGCATTCCTCCGGTT-3’), Cd44 (5’- TCGATTTGAATGTAACCTGCCG-3’; 5’- CA
GTCCGGGAGATACTGTAGC-30), Itgb1 (5’- GGACGCTGCGAAAAGATGAA; 5’- CATTCT
CCGCAAGATTTGGCA-3’), Foxc2 (5’- GCAACCCAACAGCAAACTTTC; 5’- GACGGCGT
AGCTCGATAGG-3’) were synthesized and used in the qPCR reaction, respectively.
RNA sequencing
RNA sequencing was performed by the City of Hope Integrative Genomics core facility.
cDNA synthesis and library preparation was performed using Kapa RNA mRNA HyperPrep
kit (Kapa Biosystems, Cat KR1352) in accordance with the manufacturer supplied protocols.
For gene set enrichment analysis (GSEA), genes were pre-ranked by the signed log 2 fold
change. The preranked data were uploaded to GSEA and enrichment of hallmark gene sets
were interrogated with 1,000 random permutations to obtain the P value, q value and normal-
ized enrichment score (NES).
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Statistical analyses
Cell numbers were counted manually using 40x photomicrographs as described in Fig 4F. Sta-
tistical analyses were performed using 2-tailed Student’s t test. The date was presented as the
means ± S.D and cell numbers were made comparisons between groups, using a Student’s t
test. p< 0.05 were considered significant.
Supporting information
S1 Fig. Immunohistochemical staining of P16Ink4a expression and neuroendocrine cell
staining, and mucin staining. (A) Representative P16Ink4a IHC images of prostate sample
from the R26hARL/wt: PB-Cre4 mice. Scale bar = 100 μm or 25 μm. (B) IHC analyses of synap-
tophysin staining using mouse tissues as positive controls. Representative IHC images of posi-
tive synaptophysin staining showed in the cytoplasm of scattered neuron cells in the urethral
urothelial and submucosal glands in mouse tissues samples as reported early (Toxicologic
Pathology, 2005, 33:386–397). Scale bar = 100 μm or 25 μm. (C-D) Representative Periodic
Acid Schiff (C-C’) and PAS-Diastase (D-D’) staining images from liver tissues of wild type
mice were shown as positive controls in this study. Scale bar = 100 μm or 25 μm. (E) Represen-
tative Alcian Blue staining images from intestine tissues of wild type mice were shown as posi-
tive controls in this study. Scale bar = 100 μm or 25 μm.
(PDF)
S2 Fig. Immunohistochemical staining of lung metastasis from the AR transgene and loss
of p16Ink4a compound mice. (A-F) Representative H&E and IHC images of lung metastasis
sample from the R26hARL/wt:p16L/L: PB-Cre4 mice were shown for staining with different anti-
bodies (right bottom corner). Scale bar = 50 μm.
(PDF)
S3 Fig. Heatmap of the Hallmark EMT genes enriched in the AR transgene and loss of
p16Ink4a compound mice. (A) A heatmap of 49 DEGs� 5 fold in the R26hARL/wt:p16L/L: PB-Cre4
mice that overlapped with the list of hallmark EMT genes are listed with the accession numbers of
each gene. This gene list was generated through GSEA pre-ranked analysis [44] of the DEGs that
were altered comparing p16L/L:PB-Cre4 and R26hARL/wt:p16L/L: PB-Cre4 mice. (B) Gene set Enrich-
ment analysis (GSEA) plot of Hallmark EMT gene set, NES = 2.85 FDR (q-value)<0.000001.
(PDF)
S1 Table. RNA-seq data with Log2 fold change for comparison of p16L/L:PB-Cre4 and
R26hARL/wt:p16L/L: PB-Cre4. Expression values were normalized to wild type mice and log2
transformed for the comparison between the RNA transcriptome alteration between p16L/L:
PB-Cre4 and R26hARL/wt:p16L/L: PB-Cre4 mice.
(PDF)
S2 Table. Cellular properties of human SRCC from USC Keck School of Medicine cohort
of prostate cancer patients displaying SRCC. Seven clinical prostatectomy specimens with
signet ring prostatic carcinoma component were mounted on one TMA (tissue microarray)
and analyzed for AR, p16, CK8, CK5 and SPP1. “+” indicates pathologist determined classifica-
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